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An Old Dog with New Tricks: 99mTcsestamibi SPECT-CT for Differentiation
of Renal Masses
Zachary Beswick, M.D.
Ishani Dalal, M.D.
Henry Ford Hospital – Detroit, Michigan

RENAL CELL CARCINOMA (RCC)
 80-85% of primary renal
malignancies
 Relatively more common in
North America
 Men > Women
 Risk factors include smoking,
obesity, and hypertension
 Subtypes
 Clear cell (75-85%)
 Papillary (10-15%)
 Chromophobe (5-10%)

Image via
https://ru.wikipedia.org/wiki/%D0%A4%D0%B0%D0%B9%D0%BB:Re
nal_clear_cell_ca_(1)_Nephrectomy.jpg

BENIGN RENAL TUMORS
 Risk of malignancy decreases with smaller tumor size
 In one study, of the benign resected tumors, 75% were
oncocytomas and 11% were angiomyolipomas
 Oncocytoma
 Well differentiated neoplastic cells which behave benignly
 Difficult to distinguish from RCC histologically
 Homogenous solid mass, which may have a central scar
 Angiomyolipoma

 Enhancing mass with macroscopic fat and without
calcification

DIFFERENTIATION CHALLENGES OF
RENAL MASSES
 Limited ability to distinguish malignant and
benign solid renal masses on cross-sectional
imaging
 Limitations of percutaneous renal biopsy:

Poor negative predictive value
Tumors incapable of being biopsied
Invasive procedure

MECHANISM OF ACTION


99mTc-sestamibi

is a lipophilic cation which
localizes to cells based on mitochondrial
content

 Renal oncocytomas have large numbers
of mitochondria, especially in comparison
to renal cell carcinoma (RCC) which have
a relative paucity of mitochondria

Oncocytoma

 RCCs also often possess drug pumps that
move 99mTc-sestamibi out of the cells
 As a result, renal oncocytomas
demonstrate significant radiotracer
uptake, while RCCs demonstrate limited
uptake
Renal Cell Carcinoma

INTERPRETATION
 Renal parenchyma displays high
uptake of 99mTc-sestamibi
 RCCs generally show a distinct
decrease in radiotracer uptake
relative to surrounding normal
parenchyma

RCC patterns

 In contrast, oncocytomas display
uptake that is usually increased or
similar to that of renal
parenchyma
 Masses displaying variable
uptake are likely to be benign if
any portion displays a moderate
to high amount of uptake

Benign patterns

Post contrast T1 fat-saturated MR image shows a 1.6 cm T1 mildly
hyperintense posterior renal mass concerning for RCC, prompting 99mTcsestamibi SPECT-CT

99mTc-sestamibi

uptake within the mass is of similar intensity to surrounding renal
parenchyma, a pattern consistent with a benign renal mass and inconsistent with
RCC

A photopenic defect is seen over the posteromedial renal mass, this lack of
any discernable radiotracer uptake indicates that this lesion is unlikely to be
benign and more likely represents RCC

PITFALLS

MANAGEMENT ROLE

 Uptake misrepresentation
due to respiratory motion

 Potential to be used instead of
or in concert with renal biopsy
for risk stratification of small
renal masses

 Inability to distinguish
radiotracer uptake or lack
of uptake when evaluating
smaller lesions

 Major benefit in preventing
kidney resections due to
benign masses misclassified
as malignant
 Opportunity for decreased
morbidity from renal biopsies

